TY  - BOOK
AU  - Toumi,Mondher
AU  - Jaroslawski,Szymon
TI  - Managed entry agreements and funding for expensive therapies
T2  - Pharmaceuticals, health economics and market access
SN  - 9781000594676
AV  - RA410.5 
PY  - 2022///
CY  - Boca Raton
PB  - CRC Press
KW  - Medical care
KW  - Cost control
KW  - Drugs
KW  - Testing
KW  - Prices
KW  - Drug accessibility
KW  - Electronic books
N1  - Includes bibliographical references and index; Introduction to managed entry agreements -- From coverage with evidence development to individual performance-based agreements in Italy -- Coverage with evidence development for multiple sclerosis drugs in the UK -- a "costly failure"? -- Novel funding models for expensive therapies -- Definition and classification of MEAs -- Country comparison of the implementation of managed entry agreements
N2  - "Managed Entry Agreements and Funding for Expensive Therapies examines the concept of MEA, detailing how depreciation of some specific therapies through intangible amortization is unavoidable"--
UR  - https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=3282745
ER  -